Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPVN20 in advanced Rod-Cone Dystrophy
NCT07807111Phase 2Recruiting
- Sponsor
- SparingVision
- Start
- Oct 2025
- Primary completion
- Mar 2032
- Countries
- 3
01
Overview
A Phase 2 trial of SPVN20 in rod-cone dystrophy (RCD), retinitis pigmentosa (RP), sponsored by SparingVision. Started Oct 2025; status: recruiting.
02
Drugs
SPVN20
03
Conditions
rod-cone dystrophy (RCD)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT07807111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807111.